Emergen Research Logo

Rising occurrences of target conditions and advancements in biomedical technology are among the significant factors influencing market revenue growth

VANCOUER, BC, CANADA, September 22, 2022 /EINPresswire.com/ -- The global biologics market is projected to reach USD 567.96 Billion in 2028 at a steady revenue CAGR of 8.4% over the forecast period, according to latest analysis by Emergen Research. Some key factors attributed to steady market revenue growth include rising demand for monoclonal antibodies, recombinant hormones/proteins, gene-based & cellular-based biologics, vaccines, and molecular therapy, etc. in the treatment of diseases including cancer, infectious diseases, immunological diseases, cardiovascular diseases, and hematological diseases, among others. Also, rising use of biologics for the treatment of autoimmune diseases, comprising various arthritis types, including ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis, is playing a crucial role in driving revenue growth of the global biologics market. Biologics function by creating an inflammation disruption, thereby resulting in a reduction in joint pain.

Surging demand and higher adoption of novel biologics drugs and therapies across the globe for the treatment of disease conditions is a significant factor causative of steady market revenue growth. One such novel drug is Antibody-Drug Conjugate (ADC), which is a highly effective drug used in disease treatment. In cancer treatment, ADC delivers drugs to the disease/target cells with a very high specificity, thereby maximizing efficacy and lessening systemic exposure, as well as associated side effect risks. Based on payload attached to the antibody, ADC can be deployed to influence several biological functions.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐓𝐨 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐑𝐞𝐩𝐨𝐫𝐭 :- https://www.emergenresearch.com/request-sample/61

It offers detailed insights into the impact of COVID-19 on the industry at a regional level and industry level. The report also covers the developments and government regulations related to COVID-19. The report further analyzes the current and future impact of COVID-19 on the global market and provides an insight into the post-COVID-19 situation.

𝐒𝐨𝐦𝐞 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 :

In September 2020, Biocon Biologics Ltd. and Mylan made an announcement about the introduction of biosimilar Semglee in the US. This biosimilar is available, both in pre-filled pen and vials, and is intended for controlling high blood pressure in adults having type 2 diabetes and pediatric patients having type 1 diabetes.

Among the source segments, mammalian segment revenue is expected to register a significantly rapid growth rate over forecast period. Expression systems deploying mammalian cells for recombinant hormones/proteins can introduce appropriate protein folding, PTM (post-translational modifications), and product assembly that are essential for overall biological activity.

Among the product type segments, vaccines segment revenue is expected to expand at a relatively faster rate over forecast period. A vaccine functions by preparing the immune system to identify and fight pathogens, either bacteria or viruses. Vaccines are beneficial in reducing preventable infectious diseases, and currently, fewer number individuals suffer from the distressing effects of pertussis and measles, among other illnesses. Presently, vaccines are witnessing spiraling demand across the globe to curb the spread of COVID-19 and resulting mortalities occurring due to the disease.

Among the application segments, the cancer segment accounted for largest revenue share in 2020. Biologics assists the immune system in quickly recognizing cancer cells in the human body, as well as attacking the malignant cells, switching on/off the signals from cancerous cells and aiding in dodging the immune system cells.

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐧𝐜𝐥𝐮𝐝𝐞 : Novo Nordisk A/S, Pfizer Inc., Amgen, Sanofi, Samsung BioLogics, Merck & Co. Inc., Celltrion, AbbVie Inc., Johnson & Johnson Services Inc., Eli Lilly & Company, F Hoffman La Roche, Addgene, Novartis AG, and GlaxoSmithKline.

𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬 𝐨𝐧 𝐭𝐨𝐩 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐝𝐚𝐭𝐚 𝐟𝐨𝐫 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 @ https://www.emergenresearch.com/industry-report/biologics-market

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

𝐄𝐦𝐞𝐫𝐠𝐞𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐡𝐚𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐛𝐚𝐬𝐢𝐬 𝐨𝐟 𝐬𝐨𝐮𝐫𝐜𝐞, 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐭𝐲𝐩𝐞, 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧, 𝐚𝐧𝐝 𝐫𝐞𝐠𝐢𝐨𝐧:

𝐒𝐨𝐮𝐫𝐜𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧; 𝟐𝟎𝟏𝟖-𝟐𝟎𝟐𝟖)
Microbial
Mammalian
Others

𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐓𝐲𝐩𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧; 𝟐𝟎𝟏𝟖-𝟐𝟎𝟐𝟖)
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-Based Biologics
Gene-Based Biologics
Others

𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧; 𝟐𝟎𝟏𝟖-𝟐𝟎𝟐𝟖)
Cancer
Infectious Diseases
Immunological Diseases
Cardiovascular Diseases
Hematological Disorders
Others

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.emergenresearch.com/request-for-customization/61

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

The global Biologics Market has been categorized on the basis of key geographical regions into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. It evaluates the presence of the global Biologics Market in the major regions with regards to market share, market size, revenue contribution, sales network and distribution channel, and other key elements

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 @ https://www.emergenresearch.com/request-sample/61

𝐀𝐛𝐨𝐮𝐭 𝐄𝐦𝐞𝐫𝐠𝐞𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Emergen Research is a Market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer Market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

𝐓𝐡𝐚𝐧𝐤 𝐲𝐨𝐮 𝐟𝐨𝐫 𝐫𝐞𝐚𝐝𝐢𝐧𝐠 𝐨𝐮𝐫 𝐫𝐞𝐩𝐨𝐫𝐭. 𝐅𝐨𝐫 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐝𝐞𝐭𝐚𝐢𝐥𝐬 𝐨𝐫 𝐭𝐨 𝐢𝐧𝐪𝐮𝐢𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧, 𝐩𝐥𝐞𝐚𝐬𝐞 𝐥𝐞𝐭 𝐮𝐬 𝐤𝐧𝐨𝐰. 𝐖𝐞 𝐰𝐢𝐥𝐥 𝐨𝐟𝐟𝐞𝐫 𝐲𝐨𝐮 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐬 𝐩𝐞𝐫 𝐲𝐨𝐮𝐫 𝐧𝐞𝐞𝐝𝐬.

Eric Lee
Emergen Research
+91 90210 91709
sales@emergenresearch.com
Visit us on social media:
Facebook
Twitter
LinkedIn